Primary and secondary outcomes after ibrutinib initiation, including treatment responses, DOR, discontinuations, dose reductions, median PFS, and OS
| Outcome . | Result . |
|---|---|
| Median PFS (95% CI), mo | 5.8 (4.5-10.1) |
| Median OS (95% CI), mo | 12.0 (7.7-19.0) |
| Best response, n (%) | |
| CR | 31 (21.8) |
| PR | 31 (21.8) |
| Clinical remission | 17 (12.0) |
| SD | 8 (5.6) |
| No clinical response | 14 (9.9) |
| PD | 41 (28.9) |
| Missing | 4 |
| ORR, % | 55.6 |
| Median DOR (95% CI) , mo | 14.3 (7.7-20.7) |
| Discontinuations, n (%) | 113 (77.4) |
| Discontinuation reason, n (%) | |
| Therapy-related toxicity | 28 (19.2) |
| Progression/no response | 70 (47.9) |
| Other reasons | 15 (10.3) |
| Median OS after ibrutinib discontinuation (95% CI), mo | 1.9 (1.2-5.4) |
| Discontinuation owing to insufficient response or progression | 1.3 (0.8-2.6) |
| Discontinuation owing to therapy-related toxicity or other reasons | 11.2 (1.7-20.3) |
| Any relapse or progression on ibrutinib, n (%) | 110 (75.3) |
| Outcome . | Result . |
|---|---|
| Median PFS (95% CI), mo | 5.8 (4.5-10.1) |
| Median OS (95% CI), mo | 12.0 (7.7-19.0) |
| Best response, n (%) | |
| CR | 31 (21.8) |
| PR | 31 (21.8) |
| Clinical remission | 17 (12.0) |
| SD | 8 (5.6) |
| No clinical response | 14 (9.9) |
| PD | 41 (28.9) |
| Missing | 4 |
| ORR, % | 55.6 |
| Median DOR (95% CI) , mo | 14.3 (7.7-20.7) |
| Discontinuations, n (%) | 113 (77.4) |
| Discontinuation reason, n (%) | |
| Therapy-related toxicity | 28 (19.2) |
| Progression/no response | 70 (47.9) |
| Other reasons | 15 (10.3) |
| Median OS after ibrutinib discontinuation (95% CI), mo | 1.9 (1.2-5.4) |
| Discontinuation owing to insufficient response or progression | 1.3 (0.8-2.6) |
| Discontinuation owing to therapy-related toxicity or other reasons | 11.2 (1.7-20.3) |
| Any relapse or progression on ibrutinib, n (%) | 110 (75.3) |
PD, progressive disease; SD, stable disease.